Back to News
Market Impact: 0.3
Alumis Reports Positive Phase 3 Data With Envudeucitinib
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Alumis announced envudeucitinib data from its ONWARD Phase 3 program, including ONWARD1, ONWARD2 and the long-term extension ONWARD3. The company said the results reinforced the drug’s potential as a leading oral therapy; the provided article excerpt ends before reporting specific results or figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ALMS0.60
More News
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- MTY Food Group Inc Profit Retreats In Q3
- Why is T-Mobile stock tumbling today?
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper